Aerovate Therapeutics furnishes corporate presentation; no material news disclosed

Jade Biosciences, Inc.

Filed under Item 7.01 as Regulation FD disclosure; presentation used for investor meetings starting March 27, 2024.
Presentation focuses on pipeline for pulmonary arterial hypertension; no new clinical or financial data provided.
No specific numbers, milestones, or guidance changes were included in the exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.